Health and Healthcare
How Analysts Value Gilead Now After Earnings
Published:
Last Updated:
Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter financial results on Tuesday. As a result, analysts weighed in on this biotech giant and in what direction it might go next.
The company had $3.32 in earnings per share (EPS) on $8.51 billion in revenue, versus Thomson Reuters consensus estimates that called for $3.00 in EPS on revenue of $8.13 billion. The same period from the previous year had EPS of $2.43 on $7.31 billion in revenue.
In the fourth quarter of 2015, product sales in the United States were $4.8 billion, compared to $5.5 billion in the fourth quarter of 2014. In Europe, product sales were $1.7 billion, compared to $1.4 billion a year ago. Sales in other international locations increased to $1.9 billion, compared to $373 million.
Harvoni sales totaled $3.35 billion in the fourth quarter, compared to $2.11 billion last year. Sovaldi sales totaled $1.55 billion this year, which came down from $1.73 billion.
As for full-year 2016 guidance, Gilead expects to have net product sales in the range of $30 billion to $31 billion, compared to the consensus estimate of $31.68 billion in revenue.
Shares of Gilead closed Friday at $85.14, with a consensus analyst price target of $118.28 and a 52-week trading range of $81.89 to $123.37.
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.